HAEMATO AG Stock Xetra

Equities

HAE

DE000A289VU3

Pharmaceuticals

End-of-day quote Xetra 06:00:00 2024-02-04 pm EST 5-day change 1st Jan Change
26.2 EUR -0.76% Intraday chart for HAEMATO AG -1.50% -5.76%
Sales 2023 * 270M 287M Sales 2024 * 281M 299M Capitalization 112M 119M
Net income 2023 * 7M 7.45M Net income 2024 * 9M 9.58M EV / Sales 2023 * 0.34 x
Net cash position 2023 * 21.3M 22.68M Net cash position 2024 * 24.3M 25.87M EV / Sales 2024 * 0.31 x
P/E ratio 2023 *
14.3 x
P/E ratio 2024 *
11.8 x
Employees -
Yield 2023 *
5.05%
Yield 2024 *
5.37%
Free-Float 99.67%
More Fundamentals * Assessed data
Dynamic Chart
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
21.4 EUR
Average target price
33 EUR
Spread / Average Target
+54.21%
Consensus

Quarterly revenue - Rate of surprise